Search Results (55)

Background/Objectives: Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder caused by recurrent upper-airway collapse during sleep, leading to intermittent hypoxia, sleep fragmentation, and excessive daytime sleepiness. Although continuous positive airway pressure (CPAP) remains the first-line therapy, long-term adherence is often suboptimal, underscoring the need for more tolerable and flexible treatment options. This review aims to summarize the pathophysiological rationale for pharmacotherapy in OSA and to discuss recent developments in drug-based interventions. Methods: We conducted a narrative review of the literature on pharmacological interventions for OSA, with a systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to 4 August 2026. We included randomised controlled trials, observational studies, meta-analyses, and mechanistic human or animal studies that reported relevant sleep and respiratory outcomes, and graded evidence according to the principles of GRADE framework. Results: Several drug classes have shown promise: agents that increase upper-airway dilator muscle activity, respiratory stabilizers that reduce loop gain, medications that raise the arousal threshold, topical anti-inflammatory drugs for mucosal edema, and systemic metabolic modulators such as glucagon-like peptide-1 receptor agonists and dual incretin receptor agonists. Emerging strategies, including gene therapy directed at the hypoglossal motor system, are also under investigation at the preclinical stage. Moreover, combining pharmacotherapy with CPAP or other devices can produce synergistic benefits, enabling lower device pressures and enhanced patient comfort. Conclusions: Pharmacotherapy for OSA is progressively moving from exploratory research towards targeted, phenotype-driven personalized treatment. Future studies should focus on robust patient phenotyping, multi-mechanistic combination regimens, and long-term clinical outcome evaluations to facilitate the integration of drug-based therapies into routine OSA management, particularly in specific subgroups such as those with COMISA. Full article

Background/Objectives: Children with cancer admitted to the pediatric intensive care unit (PICU) are at increased risk for post-intensive care syndrome (PICS-p) due to prolonged immobility, deep sedation, and severe illness. The ABCDEF bundle offers a framework for enhancing ICU care and patient recovery, but implementing all components in pediatric oncology patients is challenging. This study assesses the development and implementation of the BRAVE (Beginning Restorative Activities Very Early) initiative, specifically BRAVE2, to integrate the comprehensive ABCDEF bundle and a nurse-led mobility program, in collaboration with rehabilitation specialists, within a pediatric oncology intensive care unit. Methods: BRAVE2 was a quality improvement project conducted in a single pediatric ICU from 2022 to 2023. We analyzed ICU data to assess patient demographics, frequency of physical and occupational therapy (PT/OT) consultations, time to initial mobilization, and delirium screening rates (CAPD score of 9 or higher) for patients with ICU stays over 48 h. BRAVE2 addressed all elements of the ABCDEF bundle, including regular pain assessments, evaluation of spontaneous breathing readiness, sedation adjustments, delirium screening, early mobilization, and family engagement. Outcomes were monitored using statistical process control methods. Results: Of 140 patients, 117 (84%) remained in the ICU for more than 48 h. The delirium screening rate was 15.5%, consistently below the target of 30%. PT/OT consultations within 72 h occurred in 80.7% of patients, and early mobilization in 49.7% of patients, both below the 80% goal. However, 90.4% of patients with tracked mobility were able to ambulate during their ICU stay. No mobility-related safety incidents were reported. Conclusions: Rolling out a full ICU liberation plan in a pediatric oncology ICU is possible, and implementing a comprehensive one is feasible and sustainable despite challenges. Although therapist-led early mobilization did not meet targets, incorporating nurse-led mobility strategies and routine delirium screening has established a scalable model to enhance ICU care and support long-term recovery for these patients. Full article

Incretin-based therapies have transformed the management of obesity and type 2 diabetes mellitus (T2DM). Established agents—the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide—are now widely used, while a diverse pipeline of multi-receptor agents is advancing through late-phase development. GLP-1 receptors are expressed in several oral and other craniofacial tissues, raising the question of how these drugs affect oral health. This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov; January 2010–June 2026) integrates mechanistic studies, randomised controlled trials, pharmacovigilance data, society guidance, and the patient-facing phenomena increasingly raised in the dental chair. Preclinical and limited clinical evidence suggests that GLP-1 RAs may attenuate periodontal inflammation, while their effects on alveolar bone remain uncertain, reflecting both direct receptor and indirect metabolic influences. Concurrently, gastrointestinal adverse effects (nausea, vomiting, belching), reduced fluid intake, and possible salivary changes underlie a cluster of patient-reported complaints colloquially termed “Ozempic mouth”, “Ozempic teeth”, and “Ozempic breath”, alongside the facial soft-tissue changes seen in “Ozempic face”. Human oral-health-endpoint data remain scarce; much evidence is preclinical, indirect, or derived from case-level or pharmacovigilance reports. The oral cavity is nonetheless a plausible direct target of incretin pharmacotherapy and a practical monitoring site for tolerability. Dental practitioners should proactively manage the oral consequences of these agents, and validated oral health endpoints should be incorporated into future incretin trials. Full article

Atrial fibrillation (AF) and diabetes mellitus frequently coexist and together define a high-risk cardiometabolic phenotype. Diabetes is associated with an increased incidence of AF, although this relationship is strongly influenced by obesity, hypertension, chronic kidney disease (CKD), heart failure (HF), sleep-disordered breathing, and broader metabolic risk clustering. Once AF develops, diabetes is associated with greater thromboembolic and HF risk, impaired quality of life, cognitive vulnerability, and excess mortality. These adverse outcomes may be partly explained by a multidimensional atrial substrate, described here within the conceptual framework of diabetic atrial cardiomyopathy, in which hyperglycaemia, insulin resistance, glycaemic variability, oxidative stress, inflammation, autonomic dysfunction, microvascular disease, lipotoxicity, and epicardial adipose tissue dysfunction may contribute to atrial fibrosis, electrical heterogeneity, impaired calcium handling, mitochondrial injury, and mechanical dysfunction. Collectively, these abnormalities may facilitate AF initiation, persistence, progression, and recurrence after rhythm-control interventions. Management should therefore extend beyond rhythm control and anticoagulation alone. In individuals at increased risk of AF, priorities include cardiometabolic optimization, treatment of obesity, hypertension, CKD, HF, and sleep apnoea, lifestyle intervention, and selective rhythm surveillance. In subclinical AF, decisions regarding anticoagulation should account for AF burden, thromboembolic and bleeding risk, renal function, frailty, and patient preference. In established AF, stroke prevention, symptom-directed rate or rhythm control, cardiometabolic therapy, and longitudinal reassessment remain central. This narrative review integrates the epidemiology, mechanisms, and management of AF in diabetes across the continuum from AF risk to subclinical and clinical disease. Full article

Background/Objectives: Obstructive sleep apnea (OSA) and related sleep disorders affect a substantial proportion of hospitalized patients, with an estimated 48% pooled prevalence of undiagnosed OSA in cardiac inpatients and up to 80% of moderate-to-severe community OSA cases carrying no formal diagnosis at the time of hospital admission. In parallel, frailty—a state of heightened physiological vulnerability arising from cumulative multi-system biological decline—is present in 40–80% of inpatients and shares deep, bidirectional neurobiological pathways with sleep-disordered breathing through circadian dysregulation, intermittent hypoxia, hypothalamic–pituitary–adrenal axis activation, and chronic low-grade inflammation. Despite this convergence, no prior study has integrated validated, administratively computable frailty phenotyping with a machine learning framework specifically designed to predict inpatient sleep disorder diagnosis—and OSA in particular—at the point of hospital admission. The present study addresses this gap by developing an admission-time, explainable machine learning framework for the prediction of inpatient sleep disorder diagnoses (ICD-10 G47.x, encompassing OSA G47.3, insomnia G47.0, hypersomnia, and circadian rhythm disorders) and of insomnia specifically (ICD-10 G47.00). Methods: We developed and evaluated a suite of five binary classification models—XGBoost, Random Forest, LightGBM, CatBoost, and Decision Tree—using 9682 balanced hospitalization episodes from the MIMIC-IV (version 2.2) database. The predictor set comprised 23 admission-time structured features across three domains: (i) frailty and comorbidity burden, including the Hospital Frailty Risk Score (HFRS) derived from ICD-10 codes, the Elixhauser comorbidity index, prior admission history, and six binary disease flags (obesity, hypertension, type 2 diabetes, heart failure, COPD, and depression/anxiety); (ii) physiological and laboratory biomarkers from the first 24 h of care, including minimum SpO₂, heart rate variability, hemoglobin, creatinine, albumin, and arterial blood gas parameters; and (iii) sociodemographic and administrative variables encompassing age, sex, ethnicity, insurance type, and admission acuity. Model performance was assessed through five-fold stratified cross-validation and bootstrap confidence intervals (n = 1000 iterations), with predictor importance quantified using SHapley Additive exPlanations (SHAP). Results: XGBoost achieved the strongest aggregate performance across all evaluation metrics, attaining an area under the receiver operating characteristic curve (AUC) of 0.871 (95% CI: 0.856–0.887), accuracy of 79.6%, F1-score of 0.820, and sensitivity of 94.9%, correctly identifying 903 of 952 true positive cases in the held-out test set; all gradient boosting frameworks substantially outperformed the Decision Tree baseline (AUC 0.836). SHAP analysis identified the HFRS and Elixhauser index as the two dominant predictors, followed by depression/anxiety, obesity, hypertension, and minimum SpO₂—a hierarchy that recapitulates the canonical clinical phenotype of obstructive sleep apnea in frail inpatients rather than that of primary insomnia, indicating that the model is preferentially capturing the OSA–frailty axis within the broader G47.x outcome. The predicted probability outputs were well-calibrated across all risk deciles. Conclusions: Frailty-derived features, in combination with admission-time clinical and physiological data, can predict inpatient sleep disorder diagnoses—predominantly OSA—with high sensitivity and well-calibrated risk estimates. The deployable, interpretable nature of the XGBoost model makes it directly suitable for integration into clinical decision support systems, offering a screening tool that requires no dedicated instrumentation beyond routine admission data. By flagging high-risk patients at the moment of admission, the framework provides a concrete mechanism for accelerating referral for definitive diagnostic confirmation (overnight oximetry, polysomnography) and earlier initiation of CPAP and related therapies, with direct implications for reducing the persistent diagnostic gap, perioperative risk, and preventable adverse outcomes in frail hospitalized populations. Full article

Background: Chronic pain affects approximately 30% of older adults and is strongly associated with social isolation and loneliness, which impact an estimated 25% of the global older adult population. A substantial proportion of chronic pain in this population is classified as primary chronic pain (non-specific), characterized by persistent pain with no underlying disease or structural damage. Pharmacotherapy has limited efficacy in treating primary chronic pain and presents significant polypharmacy risks, highlighting a critical need for sustainable, non-pharmacologic interventions. Among these, Tai Chi has emerged as a promising multimodal therapy, it is a mind–body exercise that integrates gentle movement and focused breathing with social engagement, offering participants both physical relief and opportunities for meaningful human connection. Gentle movement for flexibility, balance, and strength, combined with deep breathing may also improve self-reported symptoms of chronic pain, in addition to inflammatory biomarkers such as CRP, IL-6 and TNFα. The purpose of this narrative review is to investigate the literature on Tai Chi as a method for promoting socialization and reducing self-rated chronic pain among community-dwelling, socially isolated older adults. Methods: Following librarian-assisted concept map development, we searched six electronic databases (PubMed, CINAHL, Scopus, Cochrane, ProQuest, and PsycINFO) for studies published between January 2016 and February 2026. Search strings included terms for “older adults,” “chronic pain,” “social isolation/loneliness,” and “Tai Chi.” Two reviewers independently screened results and extracted data for relevance. Results: Of the 1098 records identified, 25 studies met the inclusion criteria. Eleven studies evaluated Tai Chi or related mind–body interventions. Among these, approximately six studies reported improvements in pain-related outcomes, while five studies reported improvements in loneliness or social isolation. However, only two to three studies simultaneously evaluated both chronic pain and social isolation/loneliness outcomes within Tai Chi interventions. Overall, most studies supported Tai Chi as a safe and potentially effective intervention for older adults, with evidence suggesting benefits for both pain and social well-being. However, the limited number of studies examining combined outcomes restricts conclusions regarding the integrated effects of Tai Chi on chronic pain and social isolation. Discussion: Tai Chi is a safe, inexpensive behavioral strategy for improving social connectedness and reducing self-rated chronic pain among older adults. However, the evidence base remains fragmented, as pain and social isolation are rarely assessed together within the same trial. Future research should address this gap by considering both social isolation and chronic pain in the same study, with more standardized Tai Chi forms as the single independent variable. Full article

Background/Objectives: Orofacial myofunctional therapy (OMT) is a system of targeted neuromuscular exercises and behavioral retraining intended to optimize tongue, lip, jaw, and airway function during rest, breathing, swallowing, and sleep. Historically associated with tongue thrust and abnormal swallowing, OMT is now applied across an expanding range of clinical contexts, including sleep-disordered breathing (SDB), tongue-tie rehabilitation, orthodontic stability, and perioperative functional recovery. As its use has broadened, persistent questions have followed: what is myofunctional therapy, where did it originate, and how did a set of oral exercises evolve into an intervention increasingly integrated with airway health, sleep medicine, and surgical care? Methods: This article presents a narrative historical review with a perspective component, synthesizing foundational literature, interdisciplinary contributions, and selected contemporary evidence to examine the evolution of OMT from ancient functional practices to modern clinical science. It is written to trace recurring clinical observations, shifts in educational frameworks, and key inflection points that shaped how OMT has been taught and applied over time. Results: OMT did not emerge from randomized controlled trials or standardized protocols. It arose from repeated clinical encounters with patients with atypical craniofacial development, relapse of structural correction, persistent mouth breathing, and/or unresolved swallowing and speech dysfunction despite technically successful treatment. These patterns suggested that anatomy alone could not account for outcome variability. Over time, clinical attention expanded beyond isolated tongue function to include breathing patterns, posture, neuromuscular tone, and airway behavior. In the past two decades, controlled trials, cohort studies, and systematic reviews have supported selected applications of OMT, particularly in SDB and adjunctive airway care, while also revealing ongoing challenges related to training variability, terminology, scope of practice, and standardization. Conclusions: OMT has historically been described as a system of targeted neuromuscular and behavioral interventions aimed at modifying orofacial rest posture and function. Over time, the field has expanded beyond localized muscle retraining toward a broader functional framework that integrates airway physiology, craniofacial growth, sleep, and interdisciplinary rehabilitation. Full article

Background: Peripheral venous cannulation is one of the most common clinical procedures, yet it often causes significant pain, anxiety, and discomfort for patients. While pharmacological methods exist, non-pharmacological interventions offer a low-cost, low-risk alternative that eliminates waiting times for anesthetic onset. The aim of this review is to synthesize the various nonpharmacological interventions for procedural pain reduction during PIVC in adults, covering interventions ranging from psychological distraction to advanced procedural support technologies. Methods: A systematic review was conducted following PRISMA 2020 guidelines and the Joanna Briggs Institute (JBI) framework. Databases including PubMed, CINAHL, Web of Science, and Scopus were searched for studies published between 2015 and 2025. Inclusion criteria focused on randomized controlled trials (RCTs) and quasi-experimental studies involving adult patients undergoing PIVC. Results: Thirty studies (29 randomized controlled trials and one experimental study) were included in the final analysis. The interventions were categorized into three primary groups: distraction techniques, physical methods, and behavioral techniques. The application of virtual reality (VR), optical illusion cards, and music therapy significantly reduced pain scores and enhanced patient satisfaction. Similarly, physical methods, such as thermomechanical stimulation (e.g., the Buzzy^® device), local heat application, and vibration, were found to be effective in lowering pain intensity compared to standard care. Behavioral techniques, including the “cough trick,” diaphragmatic breathing, and the Valsalva maneuver, consistently demonstrated efficacy in reducing both procedural pain and anxiety. Notably, while most interventions successfully reduced pain, certain methods—such as near-infrared (NIR) vein visualization—improved procedural success rates without significantly altering the subjective perception of pain. Conclusions: Findings from this review suggest that non-pharmacological interventions may serve as effective, safe, and feasible adjuncts for pain management during peripheral venous cannulation. Techniques such as the cough trick and vibration-based devices are particularly recommended due to their ease of integration into routine nursing practice, potentially improving patient comfort and clinical outcomes. Full article

Background: Joubert syndrome (JS) is a rare ciliopathy characterized by cerebellar and brainstem malformations and the molar tooth sign on magnetic resonance imaging. Motor impairment is primarily driven by axial hypotonia, impaired postural control, and disrupted respiratory-postural integration. Longitudinal reports describing structured neurorehabilitation with standardized functional outcomes remain limited. Case presentation: We report a female child with prenatally suspected vermian hypoplasia and postnatally MRI-confirmed Joubert syndrome. Subsequent molecular testing performed at the age of 3 years and 11 months identified heterozygous variants in the B9D2 gene associated with Joubert syndrome. Early development was marked by axial hypotonia, global motor delay, impaired trunk stabilization, sleep-disordered breathing, and early hip migration. At 2.5 years of age, following motor plateau under conventional therapy, a structured 12-month rehabilitation programme was introduced, combining Vojta-based reflex locomotion, respiratory therapy targeting thoraco-diaphragmatic synchronization, daily home-based practice, and supported standing. Results: After 12 months, gross motor function improved substantially, with GMFM-88 increasing from 12% to 52% (+40 percentage points). PEDI scaled scores improved across all domains, with mobility increasing from 8 to 40, self-care from 15 to 45, and social function from 25 to 50. Ataxia severity decreased from 22 to 15 on the modified Brief Ataxia Rating Scale, consistent with improved trunk stability and coordination. Postural and respiratory organization improved, reflected by a reduction in the subcostal angle from 137° to 90°, an increase in sacral slope from 5° to 10°, and increased expiratory pressure from 10 to 25 mmHg. Caregiver-reported assessment combined with structured clinical observation indicated improved functional visual performance, including enhanced visual attention, visuomotor coordination, and environmental visual interaction. Conclusions: Structured neurorehabilitation was associated with substantial functional improvement across motor, postural, and respiratory domains. These findings support the clinical relevance of mechanism-oriented neurorehabilitation and standardized longitudinal outcome assessment in Joubert syndrome. Full article

Background/Objectives: Breathing efficiency and stability depend on the integrated function of biochemical, biomechanical, and psychophysiological processes across the unified upper and lower airway. Clinical interventions often address these domains in isolation, which may limit treatment outcomes. The primary objective of this article is to present Integrative Breathing Therapy (IBT) as a clinically applicable, multidimensional framework for training unified airway function. A secondary objective is to illustrate how this framework can inform clinical reasoning in orofacial myology and behavioural management of obstructive sleep apnea. Method: This article presents a clinical synthesis of physiological theory, neuroplasticity research, and applied breathing therapy to describe the theoretical and clinical foundations underpinning the Integrative Breathing Therapy (IBT) framework. Multidimensional phenotyping is used to organise dominant biochemical, biomechanical, and psychophysiological contributors to breathing inefficiency, with obstructive sleep apnea presented as a clinical example. Results: This synthesis outlines a unified airway model linking multidimensional phenotyping to targeted intervention selection. The IBT framework provides a structured approach for integrating biomechanical coordination, ventilatory control, and psychophysiological regulation within clinical practice. The obstructive sleep apnea exemplar demonstrates how phenotype-informed mapping can support clinical reasoning and guide individualised intervention strategies within OM and related behavioural approaches. Conclusions: Integrative Breathing Therapy offers a clinically grounded, multidimensional model for functional breathing optimisation that aligns unified airway training with principles of neural adaptation and systems-based clinical reasoning. This framework supports phenotype-guided clinical decision-making and provides a coherent structure for addressing breathing inefficiency and airway instability across a range of clinical populations, including those treated with orofacial myology and behavioural OSA therapies. Full article

We report a thirty-six-year-old woman with intellectual disability who was referred for evaluation of suspected obstructive sleep apnea. The initial clinical impression suggested a syndromic case, so comprehensive genetic testing was undertaken. Overnight polysomnography revealed a severe rapid eye movement–predominant obstructive sleep apnea syndrome with an apnea–hypopnea index of 31.9 events per hour, rapid eye movement apnea–hypopnea index of 113.8 events per hour, and lowest oxygen saturation of 66%. Treatment with continuous positive airway pressure improved respiratory and sleep quality indices and was well tolerated. Whole-exome sequencing identified a de novo splice site variant in the pleckstrin homology domain interacting protein gene (c.41-1G > A), confirming a molecular diagnosis of Chung–Jansen Syndrome. Chung–Jansen syndrome is a rare neurodevelopmental disorder caused by heterozygous pathogenic variants in the pleckstrin homology domain interacting protein gene, marked by developmental delay, intellectual disability, behavioral abnormalities, dysmorphism, and progressive obesity. PHIP influences central and peripheral pathways controlling satiety, pancreatic function, and body weight. Despite frequent reports of sleep problems, systematic evaluation of sleep-disordered breathing has been limited. This adult case provides the first polysomnographic confirmation in the syndrome, supporting proactive screening for obstructive sleep apnea—especially in those with obesity. Integrating genetic assessment into sleep care can reduce diagnostic delays and better guide therapy and prognosis. Full article

Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder associated with significant cardiometabolic morbidity, impaired neurocognitive functioning, daytime sleepiness, and reduced quality of life. Although continuous positive airway pressure (CPAP) therapy remains the cornerstone of treatment for moderate-to-severe OSA, long-term adherence is frequently suboptimal, and a substantial proportion of patients experience residual symptoms despite adequate therapy. These limitations have driven increasing interest in non-CPAP treatment strategies and, more recently, in pharmacological approaches tailored to specific OSA pathophysiological mechanisms. This narrative review provides an updated overview of non-CPAP therapies for OSA, including oral appliances, surgical interventions, positional therapy, hypoglossal nerve stimulation, and behavioral strategies, with a particular focus on emerging and established pharmacological treatment and their role in endotype/phenotype-guided management of OSA. Overall, the expanding pharmacological landscape of OSA reflects a paradigm shift toward personalized, multimodal management. Integrating non-CPAP and pharmacological therapies with patient-specific pathophysiology may improve symptom control, adherence, and long-term outcomes in OSA. Full article

Cardiogenic pulmonary edema (CPE) is a life-threatening manifestation of acute heart failure characterized by rapid accumulation of fluid in the interstitial and alveolar spaces, leading to severe dyspnea, hypoxemia, and respiratory failure. The condition arises from elevated left-sided filling pressures that increase pulmonary capillary hydrostatic pressure, disrupt alveolo-capillary barrier integrity, and impair gas exchange. Neurohormonal activation further perpetuates congestion and increases myocardial workload, creating a vicious cycle of hemodynamic overload and respiratory compromise. Respiratory support is a cornerstone of management in CPE, aimed at stabilizing oxygenation, reducing the work of breathing, and facilitating ventricular unloading while definitive therapies, such as diuretics, vasodilators, inotropes, or mechanical circulatory support (MCS), address the underlying cause. Among available modalities, non-invasive ventilation (NIV) with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) has the strongest evidence base in moderate-to-severe CPE, consistently reducing the need for intubation and providing rapid relief of dyspnea. High-flow nasal cannula (HFNC) represents an emerging alternative in patients with moderate hypoxemia or intolerance to mask ventilation, and should be considered an adjunctive option in selected patients with less severe disease or NIV intolerance, although its efficacy in severe presentations remains uncertain. Invasive mechanical ventilation is reserved for refractory cases, while extracorporeal membrane oxygenation (ECMO) and other advanced circulatory support modalities may be necessary in cardiogenic shock. Integration of respiratory strategies with hemodynamic optimization is essential, as positive pressure ventilation favorably modulates preload and afterload, synergizing with pharmacological unloading. Future directions include personalization of ventilatory strategies using advanced monitoring, novel interfaces to improve tolerability, and earlier integration of MCS. In summary, respiratory support in CPE is both a bridge and a decisive therapeutic intervention, interrupting the cycle of hypoxemia and hemodynamic deterioration. A multidisciplinary, individualized approach remains central to improving outcomes in this high-risk population. Full article

High-flow nasal cannula (HFNC) therapy is frequently described as a positive pressure modality, yet this classification lacks mechanistic support. This critical narrative review integrates experimental, computational, and clinical evidence to examine the established physiological mechanisms underlying HFNC, with emphasis on precise terminology. The study clarifies that labeling HFNC as “positive pressure” is conceptually inaccurate, as the system delivers transient, flow-dependent pressures characteristic of open-circuit administration. Evidence is synthesized to quantify the relative contributions of nasopharyngeal dead-space clearance versus emergent pressure generation. Unlike CPAP, HFNC produces pressures ranging from 0.2 to 13.5 cmH₂O, determined by airway geometry, leak magnitude, and mouth position. Fluid dynamic modeling using Bernoulli and Darcy–Weisbach equations demonstrates oscillatory rather than sustained pressures, with magnitudes linked to nasopharyngeal Reynolds numbers (2400–6000) and turbulent energy dissipation (30–60%). Clinical efficacy persists despite variable pressures, reflecting synergistic mechanisms: inspiratory flow matching (40–50% reduction in work of breathing), dead-space clearance (CO₂ reduction, r = −0.77, p < 0.05), emergent pressure effects (10–20%), and thermal humidification (10–20%). Electrical impedance tomography reveals heterogeneous alveolar recruitment, with high-potential (54%) and low-potential (46%) phenotypes. Based on these mechanistic insights, this review proposes the term “emergent hydrodynamic pressure” to accurately describe HFNC’s transient, flow-dependent pressures. This terminology differentiates HFNC from conventional positive pressure systems and aligns language with the principles of fluid dynamics and respiratory physiology. Full article

Background: Temporomandibular disorders (TMDs) are increasingly understood within the biopsychosocial framework, which highlights the interplay of biological, psychological, and social factors in their onset and persistence. Within this context, orofacial myofunctional disorders (OMDs) represent a significant biological component, reflecting structural and functional disturbances of the orofacial system that may contribute to temporomandibular dysfunction. Objectives: This pilot study evaluated the effectiveness of orofacial myofunctional therapy (OMT) in improving functional parameters and reducing pain in adults with myogenous TMD accompanied by OMDs. Methods: In this prospective single-arm pilot study, twenty-five adults (aged 25–39 years) with myogenous TMD and coexisting OMDs, diagnosed according to DC/TMD criteria by a dentist trained in DC/TMD assessment and referred for the intervention, completed three biweekly OMT sessions. The therapy comprised myofascial release, oromotor exercises, functional retraining of breathing, chewing, and swallowing, as well as mandibular stabilization and dissociation exercises, complemented by home-based practice. Functional parameters—maximum mouth opening (MAX) and tongue mobility (TRMR-TIP, TRMR-LPS)—were measured before and after each session. Pain intensity (VAS) and quality of life (SF-36) were assessed at baseline and post-intervention. Data were analyzed using the Shapiro–Wilk test, paired t-test, and Wilcoxon signed-rank test. Results: Statistically significant improvements (p < 0.001) were observed across all evaluated parameters. Participants demonstrated increased maximum mouth opening and tongue mobility, along with decreased pain intensity and improved quality of life following the intervention. Conclusions: This pilot study provides preliminary evidence that short-term OMT can yield measurable functional improvements and pain reduction in adults with TMD and associated OMDs. These findings underscore the relevance of addressing orofacial myofunctional impairments as part of the biological dimension within the biopsychosocial model and support the integration of OMT into interdisciplinary TMD management. Full article